Skip to main content
. 2021 Oct 10;13(1):88–95. doi: 10.34172/apb.2023.007

Table 3. Overall survival rate (months) and progression-free survival at different dosages and therapies with TPS PD-L1 ≥ 50% .

Treatment Overall survival Progression free survival
Pembrolizumab 2 mg/kg 14.9 5.0
Pembrolizumab 10 mg/kg 12.7 4.0
Docetaxel 8.2 4.1